1-800-567-8911 or
604-682-5050
(Telephone interpreting in over 150 languages available)
Onasemnogene
Trade Name:
Zolgensma
Manufacturer/Distributor:
Novartis Pharmaceuticals
Classification:
Cellular and gene therapy
ATC Class:
M09AX09 - onasemnogene
Status:
active
Notice of Compliance (yyyy/mm/dd):
2020/12/15
Date Marketed in Canada (yyyy/mm/dd):
2021/02/04
Presentation:
Solution for infusion: 2 x 10(13) vector genomes/mL. DIN: 02509695
Comments:
For treatment of pediatric patients with 5q spinal muscular atrophy.
Source:
Product monograph
Back to:
Drug Product Listings 
